Welcome to our dedicated page for Else Nutrition H news (Ticker: BABYF), a resource for investors and traders seeking the latest updates and insights on Else Nutrition H stock.
News and updates for Else Nutrition Holdings Inc. (BABYF) focus on its activities as a plant-based food and nutrition company serving infants, toddlers, children, and adults. The company’s announcements highlight its efforts to develop plant-based, non-soy, non-dairy formulas as alternatives to traditional dairy-based products, along with operational, financial, and regulatory developments that shape its trajectory.
Investors and observers following Else Nutrition’s news can find business updates, financial results, and transformation initiatives. The company has reported on cost reductions, supply chain optimization, and manufacturing efficiency improvements, as well as temporary supply constraints linked to funding for production. These disclosures provide context on how Else Nutrition is working to create a leaner organization while addressing inventory and revenue impacts.
Regulatory and policy developments are a recurring theme in the company’s news flow. Else Nutrition has issued releases discussing U.S. government budget actions and congressional directives that call on the FDA to streamline approval pathways for plant-based, non-soy, non-dairy infant formulas. The company presents these developments as important milestones for advancing its plant-based infant formula and for families seeking alternative formula options.
Corporate governance and capital markets updates also feature in Else Nutrition’s news, including information on annual general meetings, director elections, auditor appointments, share consolidations, and funding agreements. Together, these items offer a view into the company’s strategic decisions and shareholder-related matters. Readers interested in BABYF can use this news page to review historical and ongoing announcements related to product positioning, regulatory context, operational changes, and corporate actions.
Else Nutrition (OTC: BABYF) announced it has surpassed one million cans sold across its toddler and kids powder product lines as of Jan 29, 2026. The milestone is presented as evidence of accelerating consumer demand for clean, non-dairy, non-soy, gluten-free childhood nutrition.
The company highlights thousands of parent testimonials reporting improvements in GI sensitivities, CMPA, eczema and feeding issues, and says it is advancing U.S. regulatory efforts for plant-based infant formula under Operation Stock Speed.
Else Nutrition Holdings (OTCQX: BABYF, TSX: BABY) reported results from its annual general meeting held December 29, 2025. Shareholders representing 6,473,877 shares (17.30%) of issued and outstanding shares attended.
Shareholders approved setting the board size at five directors and re-elected all management nominees with individual "for" votes ranging from 97.56% to 99.17%. The meeting also approved re-appointing Kost Forer Gabbay & Kassierer (Ernst & Young member firm) as auditor, the issuance of common shares to Lind Global Fund II, LP and Lind Global Fund III, LP under existing convertible security agreements, and the continuation of the company’s stock option plan. Voting details are available on the company’s SEDAR+ profile.
Else Nutrition (OTC: BABYF / TSX: BABY) appointed Natie Zilberberg as Chief Financial Officer and Corporate Secretary effective January 5, 2026, replacing Shay Shamir. Mr. Zilberberg has 10+ years of finance experience at VC-backed firms across fintech, agrotech, and renewable energy and previously served as CFO of Tomgrow and Financial Controller at Salaryo. His background includes leading strategic financial planning, securing credit facilities, shortening reporting cycles, supporting equity and debt raises, and executing a $30 million acquisition.
Else Nutrition (OTC: BABYF) reported that 2025 was a transformational year, including company-wide cost and headcount reductions, supply-chain and manufacturing efficiency improvements, and focused marketing investments to prioritize toddler and baby cereal categories. The company said temporary production funding shortfalls in 2025 caused supply constraints and revenue losses, and expects more stable inventory and revenue growth in 2026 with improved funding and lower operating costs. In November 2025, a U.S. congressional directive and FDA funding package was signed to streamline approval pathways for non-dairy, non-soy plant-based infant formulas, which Else says improves its regulatory outlook. Else expects to pursue manufacturing efficiencies and aims for cash-flow breakeven between late 2026 and early 2027.
Else Nutrition (TSX: BABY / OTC: BABYF) announced that its 2025 annual general meeting of shareholders will be held on December 29, 2025. The company said a notice, management information circular, and form of proxy were mailed to shareholders of record as of November 10, 2025.
The company also confirmed it received TSX approval to extend the date to hold the annual general meeting.
Else Nutrition (OTC: BABYF) on Nov 18, 2025 said the Fiscal Year 2026 U.S. federal budget signed by President Trump includes Congressional report language (H. Rept. 119-172) that directs the FDA to streamline regulatory pathways and issue formal guidance for plant-based, non-soy, non-dairy infant formulas.
The company says the provision—linked to Operation Stork Speed—was advanced through its government affairs efforts and that FDA guidance work may begin as federal employees return following the government shutdown. Else states it is positioned to accelerate regulator engagement and pursue U.S. infant-formula market access once guidance is implemented.
Else Nutrition (OTC:BABYF) reported Q3 2025 results for the quarter ended Sept 30, 2025, showing a pronounced operational turnaround. Gross profit margin expanded to 34% (versus -9% in Q3 2024). Operating expenses fell 68% to $1.15M, and operating loss narrowed to $0.58M from $3.72M a year earlier. revenue was $1.66M (down from $1.79M) amid temporary out-of-stock issues. Cash at quarter-end was $91K and trade payables declined 46% to $1.53M. Management hosted a conference call Nov 17, 2025 and cited ongoing regulatory, clinical and partnership work to support future commercialization.
Else Nutrition (OTC: BABYF) rescheduled its 2025 third quarter business update conference call to 10:00 AM Eastern on Monday, November 17, 2025.
The company will discuss Q3 2025 financial results (period ended September 30, 2025), corporate progress, and other developments. Live participation is available by telephone (toll free U.S. 1-877-407-9219; international +1-412-652-1274) or via webcast at https://event.choruscall.com/mediaframe/webcast.html?webcastid=5ZSyvIjp and the Investor Relations site https://investors.elsenutrition.com/.
A webcast replay will be available on the Investor Relations site through November 17, 2026. A telephone replay will be available ~3 hours after the call through December 1, 2025 (U.S. 1-877-660-6853; international +1-201-612-7415; conference ID: 13757060).
Else Nutrition (OTC: BABYF) will host a business update conference call on Tuesday, November 18, 2025 at 10:00 AM ET to discuss third quarter 2025 financial results (period ended September 30, 2025), corporate progress and other developments.
Investors can join by telephone (toll free U.S. 1-877-407-9219; international +1-412-652-1274) or via webcast at https://event.choruscall.com/mediaframe/webcast.html?webcastid=5ZSyvIjp and the Investor Relations site. A webcast replay will be available on the Investor Relations site through November 18, 2026. A telephone replay will be available about three hours after the call through December 2, 2025 (U.S. 1-877-660-6853; international +1-201-612-7415) using conference ID 13757060.
ELSE NUTRITION (OTCQX:BABYF / TSX:BABY) approved a 1-for-10 share consolidation effective at market open on November 6, 2025. The consolidation will reduce issued and outstanding common shares from 374,114,284 pre-consolidation to approximately 37,411,430 post-consolidation, subject to rounding.
Proportionate adjustments will apply to outstanding stock options, warrants, and other convertibles. New CUSIP 290257500 and ISIN CA2902575000 will apply. Fractional shares will be rounded down if <0.5 and rounded up if ≥0.5. Registered shareholders in certificated form will receive a letter of transmittal from Computershare; DRS holders will receive automatic post-consolidation DRS statements. Non-registered holders should consult their intermediaries. Warrant holders will be notified under the applicable warrant indentures.